Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

Key facts

Sponsor

Regeneron Pharmaceuticals

Principal Investigator

Clinical Trial Management

Regeneron Pharmaceuticals

Intervention

Ubamatamab(drug)

Enrollment

220 enrolled

Eligibility

18 years · FEMALE

Timeline

2025 – 2028

Study locations (30)

• The University of Alabama at Birmingham, Birmingham, Alabama, United States
• UC San Diego Health, La Jolla, California, United States
• Cedars Sinai Medical Center, Los Angeles, California, United States
• Mayo Clinic Jacksonville, Jacksonville, Florida, United States
• University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States
• Advent Health Cancer Institute, Orlando, Florida, United States
• Tampa General Hospital Cancer Institute, Tampa, Florida, United States
• University of Chicago, Chicago, Illinois, United States
• The University of Kansas Cancer Center, Westwood, Kansas, United States
• Norton Cancer Institute, St. Matthews Clinic, Louisville, Kentucky, United States
• Massachusetts General Hospital, Boston, Massachusetts, United States
• Karmanos Cancer Institute, Detroit, Michigan, United States
• The Ohio State University Comprehensive Cancer Center, Hilliard, Ohio, United States
• Providence Cancer Institute, Portland, Oregon, United States
• West Penn Hospital of Allegheny Health Network, Pittsburgh, Pennsylvania, United States
• +15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Malignant tumor of fallopian tubes

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT07278336
  A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer
  AbbVie
• RECRUITINGNANCT06855706
  An Automated Personalized Physical Activity Intervention to Improve Immune Function and Clinical Outcomes in Stage II-IV Ovarian, Primary Peritoneal or Fallopian Tube Cancer and Newly Diagnosed Endometrial Cancer, Life on the Go 3 Study
  Roswell Park Cancer Institute
• RECRUITINGPHASE2NCT05887609
  An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib
  University of Colorado, Denver
• ACTIVE NOT RECRUITINGEARLY PHASE1NCT05053750
  TAME: A Pilot Study of Weekly Paclitaxel, Bevacizumab, and Tumor Associated Macrophage Targeted Therapy (Zoledronic Acid) in Women With Recurrent, Platinum-resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
  M.D. Anderson Cancer Center

See all trials for Malignant tumor of fallopian tubes →